Myelodysplastic Syndromes Drugs Market Size, Share, and Industry Analysis, By Drug Class (Hypomethylating Agents, Immunomodulators, Erythroid Maturation Agents, Targeted Therapies, Chemotherapy/Supportive Drugs, and Others), By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, and Others), By Route of Administration (Injectable, Oral, and Others), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast till 2034

The global myelodysplastic syndromes drugs market was valued at USD 3.20 billion in 2025. The market is projected to grow from USD 3.48 billion in 2026 to USD 6.80 billion by 2034, exhibiting a CAGR of 8.7% during the forecast period.

Myelodysplastic Syndromes (MDS) drugs are gaining importance within hematology oncology as MDS is becoming a major concern. MDS is a chronic bone marrow disorder that leads to anemia, frequent blood transfusions, infections, bleeding risks, and progression to acute myeloid leukemia in higher-risk patients. As the diagnosed elderly patient population grows, healthcare providers are placing a stronger focus on therapies that can reduce transfusion dependence, improve blood cell production, delay disease progression, and enhance patient quality of life. The market is shifting toward more targeted and disease-specific treatments, supported by regulatory approvals of novel anemia therapies and continued development of drugs for MDS. Furthermore, expanding clinical research, regulatory approvals, better molecular classification, and increasing adoption of premium therapies by major biopharmaceutical companies are strengthening the market’s long-term growth outlook.

• For instance, in March 2025, Geron Corporation received approval from the European Commission for RYTELO (imetelstat), a telomerase inhibitor, for adults with transfusion-dependent anemia due to lower-risk myelodysplastic syndromes. The development strengthened the Company’s commercial position in the market.

Furthermore, funding initiatives, strategic collaborations, acquisitions, and new product launches by key operating companies are anticipated to boost global market growth.

Myelodysplastic Syndromes Drugs Market Driver

Rising Prevalence of MDS Among the Aging Population to Drive Growth

The global market is growing steadily as MDS is becoming more common among older adults and the elderly population. As age-related bone marrow disorders become more frequently diagnosed, the number of patients requiring long-term anemia management, blood transfusion support, and disease-modifying treatment continues to rise. These factors create sustained demand for drugs that can reduce transfusion dependence, improve hemoglobin levels, and delay disease progression. Physicians are increasingly adopting targeted and tolerable therapies for long-term disease control. As a result, pharmaceutical companies are expanding their MDS-focused portfolios and investing in therapies that address patient needs.

• For instance, in April 2024, Bristol Myers Squibb announced that the European Commission expanded approval of Reblozyl (luspatercept) to include first-line treatment of transfusion-dependent anemia in adults with very low-, low-, and intermediate-risk myelodysplastic syndromes. The approval supported market growth as it widened access for the aging patient population.

Download Free sample to learn more about this report.

In November 2024, the American Cancer Society, Inc. reported that myelodysplastic syndromes are divided by the Molecular International Prognostic Scoring System (IPSS-M) risk groups with different survival years. Among these, the highest risk group had an estimated survival period of 1 year.

Myelodysplastic Syndromes Drugs Market Restraint

Limited Curative Treatment Options for Most MDS Patients May Restrain Market Growth

The growth of the global market is restrained as most available treatments focus on disease control, anemia management, transfusion reduction, or delaying progression rather than providing a complete cure. Stem cell transplantation remains the only potentially curative option for MDS. But many patients are elderly or frail, which makes them unsuitable for this intensive procedure. As a result, a large share of patients continues to depend on therapies that improve outcomes but do not fully eliminate the disease. This limits long-term treatment success, increases relapse and progression risk, and creates uncertainty around sustained survival benefit, especially in higher-risk MDS. Therefore, despite strong unmet need, the market faces slower expansion as several investigational therapies fail to deliver clear curative or survival advantages in late-stage trials.

• For instance, in July 2023, Gilead Sciences announced that it would discontinue the Phase 3 ENHANCE study of magrolimab plus azacitidine in higher-risk MDS after a planned analysis found the study was unlikely to succeed. This development highlighted the difficulty of developing curative or clearly disease-modifying therapies in higher-risk MDS, where new treatment classes have faced major clinical setbacks.

Myelodysplastic Syndromes Drugs Market Opportunity

Rising Potential of Combination Therapies with Hypomethylating Agents to Offer Lucrative Growth Opportunities

The global market is expected to offer strong growth opportunities as companies increasingly develop combination therapies. These drugs remain a key treatment backbone for higher-risk MDS. Still, their response durability is limited in many patients, which creates a need for add-on therapies that can improve remission rates and delay progression to acute myeloid leukemia. As a result, pharmaceutical and biotechnology companies are focusing on research and development to improve outcomes beyond standard monotherapy. This approach builds on an already accepted treatment platform while adding new mechanisms of action for difficult-to-treat patient groups. Therefore, combination therapies can expand the treated patient pool and offer better outcomes simultaneously.

• For instance, in June 2024, Shattuck Labs showcased positive interim data from its Phase 1B dose expansion trial of SL-172154 in combination with azacitidine for frontline higher-risk MDS and TP53-mutant AML patients. The update supported the growth opportunity for HMA-based combinations as it showed how companies are using azacitidine as a backbone therapy while adding novel immune-targeting mechanisms to address high-risk disease biology and improve outcomes in patients with limited treatment options.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Key Disease Indications, By Key Regions/Countries
• Key Industry Developments (Strategic Partnerships, Acquisitions, and Mergers)
• Pipeline Analysis, By Key Players
• Overview of Regulatory Scenario, By Key Countries/Regions
• New Product Launches, By Key Players

Analysis by Drug Class

Based on drug class, the global market is segmented into hypomethylating agents, immunomodulators, erythroid maturation agents, targeted therapies, chemotherapy/supportive drugs, and others.

The hypomethylating agents segment is likely to dominate the global myelodysplastic syndromes drugs market. The drug class has remained a key treatment backbone for many intermediate- and higher-risk MDS patients. The drugs such as azacitidine and decitabine are widely used as they can help improve blood cell production, delay disease progression, and reduce the risk of transformation to acute myeloid leukemia in selected patients. As a result, physicians continue to rely on HMAs as a standard treatment option, leading to segmental dominance. These factors have collectively encouraged key companies to invest in the research and development of innovative therapies.

• For instance, in January 2024, Taiho Oncology published final Phase 3 ASCERTAIN trial results for INQOVI, an oral fixed-dose combination of decitabine and cedazuridine, in patients with MDS and CMML. The trial was the first Phase 3 study to demonstrate pharmacologic equivalence between an oral and intravenous hypomethylating agent formulation for MDS or CMML, supporting the continued importance of HMAs while also improving treatment convenience.

Analysis by Therapy

Based on therapy, the global myelodysplastic syndromes drugs market is segmented into targeted therapy, immunotherapy, chemotherapy, and others.

The targeted therapy segment accounts for the largest share in the market. The MDS treatment landscape is shifting toward drugs that address specific disease mechanisms and patient subgroups. Products such as erythroid maturation agents, immunomodulators, telomerase inhibitors, and mutation- or pathway-focused therapies are gaining stronger adoption as they can address defined clinical needs such as transfusion-dependent anemia, lower-risk MDS, and high-risk disease progression. As a result, targeted therapy is expected to generate a larger revenue contribution over time, especially as premium branded products expand into earlier treatment lines.

• For instance, in June 2023, Bristol Myers Squibb received approval from the U.S. FDA for Reblozyl, indicated for the first-line treatment of anemia in adults with lower-risk MDS who may require regular red blood cell transfusions. The approval strengthened the targeted therapy segment given that Reblozyl became positioned before ESA use in eligible lower-risk MDS patients, expanding the role of mechanism-based anemia treatment in the market.

Analysis by Route of Administration

Based on the route of administration, the market is segmented into injectable, oral, and others.

The injectable drugs segment is estimated to dominate the global MDS drugs market, as major therapies used in MDS are administered through hospital or specialist-care settings. Azacitidine, decitabine, luspatercept, and imetelstat are important examples of therapies that are given by injection or infusion and these products are used in patients who often require close monitoring. Since MDS mainly affects older patients, injectable therapies remain strongly linked with institutional care and regular clinical follow-up. Therefore, the injectable segment is expected to remain the largest route of administration in the near term. Recent approvals by regulatory bodies for the injectable route of administration further solidify the segment dominance.

• For instance, in June 2024, Geron Corporation received U.S. FDA approval for RYTELO, an injectable telomerase inhibitor, for adults with low- to intermediate-1 risk MDS with transfusion-dependent anemia.

Analysis by Distribution Channel

Based on distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies, drug stores & retail pharmacies, and online pharmacies.

The hospital pharmacies are likely to dominate the global myelodysplastic syndromes drugs market. The treatment is largely managed through hematology centers, cancer hospitals, and specialist outpatient infusion units. These factors make hospital-based dispensing and administration more important. In addition, higher-risk MDS patients often need coordinated care involving diagnostics, transfusion services, and oncology pharmacy support. Therefore, hospital pharmacies continue to capture the largest share as they are directly connected to specialist treatment delivery and high-value injectable therapies.

• For instance, in September 2024, Biologics by McKesson was selected by Geron Corporation as a limited specialty pharmacy provider for RYTELO (imetelstat), which is approved for adults with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The development supports the dominance of hospital pharmacy-led distribution as companies are relying on pharmacy networks to manage patient access, product availability, and treatment coordination for advanced MDS therapies.

Regional Analysis

Request for Customization   to gain extensive market insights.

The market, on the basis of region, has been analyzed across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for approximately 48.0% of the global myelodysplastic syndromes drugs market in 2025. The North America market is growing strongly as the region has a well-established hematology oncology treatment network, faster access to newly approved therapies, and higher adoption of premium drugs for patients. This creates higher demand for advanced products. As a result, North America continues to generate strong market growth as companies can launch differentiated MDS drugs quickly and expand their use through specialist hematology centers.

• For instance, in October 2024, Taiho Oncology announced that oral decitabine and cedazuridine would be included in two NIH myeloMATCH precision medicine trials, including a Phase 2 study in higher-risk, IDH2-mutated MDS. This supported North America’s market growth as it showed continued U.S.-based investment in oral and precision-medicine approaches for MDS, helping reduce treatment burden and expand the role of targeted clinical trial-based therapy.

The Europe market is expected to grow at a significant CAGR during the forecast period. The regional market is witnessing growth due to centralized regulatory approvals, strong cancer-care infrastructure, and the broad use of specialist hematology centers, which are improving access. Many European patients with lower-risk MDS face long-term anemia and transfusion dependence, which increases the demand for therapies that can reduce transfusion requirements and improve quality of life. Therefore, Europe is expected to maintain steady growth as innovative products gain wider reimbursement and move into earlier lines of therapy.

• For instance, in December 2024, Geron Corporation announced that the EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of RYTELO (imetelstat) for adults with transfusion-dependent anemia due to lower-risk MDS. This supported market growth in the region and created a pathway for a first-in-class telomerase inhibitor to reach patients with limited options after erythropoietin-based therapy failure or ineligibility.

The Asia Pacific market is expected to grow at a stable CAGR during the forecast period. The emerging economies in the region are witnessing rising diagnoses of age-related hematologic disorders and increasing adoption of advanced cancer therapies. MDS is strongly linked with older age and the expanding elderly population in key Asia Pacific markets is increasing the need for anemia management, transfusion reduction, and specialist hematology care.

• For instance, in May 2024, Bristol Myers Squibb Company launched Reblozyl (luspatercept) for anemia associated with myelodysplastic syndromes after receiving manufacturing and marketing approval in January 2024. This supported Asia Pacific market growth as Japan gained access to a novel erythroid maturation agent for MDS-related anemia, helping address the transfusion burden and limited treatment options for lower-risk patients.

Key Players Covered

The global myelodysplastic syndromes drugs market is semi-consolidated, with a few players capturing significant market share and other small players retaining the remaining market share.

The report includes the profiles of the following key players.

• Bristol Myers Squibb (U.S.)
• Geron Corporation (U.S.)
• Taiho Oncology (U.S.)
• Otsuka Pharmaceutical (Japan)
• Sandoz (Switzerland)
• Amgen (U.S.)
• Teva Pharmaceutical (Israel)
• Fresenius Kabi (Germany)
• Viatris (U.S.)
• Hikma Pharmaceuticals (U.K.)

Key Industry Developments

• October 2025: Halia Therapeutics, Inc., received Orphan Drug Designation (ODD) from the U.S. FDA to its investigational medicine ofirnoflast (HT-6184) for the treatment of Myelodysplastic Syndromes (MDS). MDS constitutes a group of bone marrow disorders characterized by ineffective blood cell production and a risk of progression to acute myeloid leukemia (AML).
• September 2025: Minovia Therapeutics Ltd. received Fast Track Designation (FTD) from the U.S. FDA for the company’s lead investigational compound, MNV-201, for Myelodysplastic Syndrome (MDS), a serious age-related hematopoietic disease. The designation was added to the existing FDA Fast Track and Rare Pediatric Disease Designations for MNV-201 in the treatment of Pearson Syndrome.